Double Bond Pharmaceutical International ABNGM: DBP.B

DBP.B: Equity restored and net loss reduced as SI-053 development progressed, but funding needs persist

· Issued by Double Bond Pharmaceutical International AB

Development of SI-053 advanced, with SEK 11.85 million raised through share issues, restoring equity and supporting operations. Net loss narrowed to SEK -333,000, and the equity ratio improved to 74.9%. Ongoing need for external financing remains.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Double Bond Pharmaceutical International AB on 6ix

Story so far

Earlier from Double Bond Pharmaceutical International

Later from Double Bond Pharmaceutical International

All Double Bond Pharmaceutical International news releases